Overall verdict
Buy
7.1/10
1-year performance
-24.02%
Score breakdown
Down 24.0% over 1 year, 36% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 4.5/10.
27 analysts, target +0.3% vs the price.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services ;
and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Krx
South Korea
CEO
Mr. John Chongbo Rim
Founded
2011
Employees
5 455
Revenue / employee
835M KRW
Next earnings
January 20, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
1987000.00 KRW
52-week low
1150000.00 KRW
1-year performance
-24.02%
Declining
Year-to-date performance
-14.00%
Declining
Drawdown
-27.08%
Marked drawdown
Position in the 52-week range
36% of range
Range: 1004616.02 KRW - 1275853.66 KRW (comparables only)
The price implies growth of 19.03% per year; the company grows at 25.00%.
Gross margin 54.2%, net margin 41.1%, ROIC 15.4%, ROE 18.5%.
Net margin
41.15%
Exceptional
Sector 3.88%|S&P 13.40%
Gross margin
54.21%
High
Return on equity (ROE)
18.53%
Exceptional
Sector 3.52%|S&P 17.06%
Return on invested capital (ROIC)
15.39%
Exceptional
Free cash flow margin (FCF)
25.29%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.61x
Fair
Margin stability
30.0 pts
Very uneven
Revenue to net income
Growth
4.9/10Revenue down 10.2% over 1 year, 31.4% a year over 5, EPS 36.9% a year over 5.
Revenue (trailing 12 months)
4.6T KRW
Revenue growth (1y)
-10.23%
Declining
Revenue growth (3y)
51.83%
Strong
EPS growth (1y)
13.78%
Solid
EPS CAGR (5y)
36.88%
Exceptional
EPS revisions (3 months)
-5.98%
Sharply revised down
Valuation
6.4/10P/E 34.0x, forward P/E 37.4x, EV/EBITDA 25.3x, PEG 0.92. The multiple sits in the 7th percentile of its own 5-year history.
P/E (TTM)
34.0x
Fair
Sector 48.4x|S&P 23.6x
Forward P/E
37.4x
Expensive
EV / EBITDA
25.3x
Fair
Sector 22.6x|S&P 15.5x
PEG
0.92
Growth unpriced
Sector -0.08|S&P 0.91
Fair value (reverse DCF)
1140234.84 KRW
Overvalued
P/E vs its own 5-year history
among the 7% lowest valuations
Far cheaper than usual
Market cap
68.4T KRW
Financial strength
10.0/10Cash covers 178.3% of the debt, net debt/EBITDA -0.2x.
Net debt / EBITDA
-0.2x
Very solid
Gearing (net debt / equity)
-13.04%
Net cash
Cash
2.2T KRW
Cash / market cap
3.24%
Tight
Cash / total debt
178.28%
Net cash
Interest coverage
43.7x
Very solid
Net debt
-972Md KRW
Equity
7.5T KRW
Closed daily candles, 2 years
Last close on November 11, 2026: 1,430,000.00 KRW
- MM201,423,550.00
- MM501,403,280.00
- MM2001,500,480.00
- RSI 1450.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.49%
200-day average slope, 3 months
-5.21%
50-day average slope, 1 month
-3.69%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
4.28 % per day
Volatility change
+52.51%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 38719.67 (15) | 38761.64 (18) | 5 585 852 (19) | 2 893 772 (20) | 1 828 447 (16) |
| 2027 | 46288.76 (18) | 46404.50 (22) | 6 491 435 (23) | 3 339 839 (21) | 2 219 065 (19) |
Amounts in millions of KRW, EPS in KRW per share. In brackets, the number of analysts. Consensus as of November 4, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 51.1Md USD | 34.0x | 41.1 % | -10.2 % | 15.4 % | -0.2x | 1.7 % | -24.0 % | ||
| 4 | A | 6.5 | 6.0 | 49.9Md USD | 34.8x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.5 % | 20.4 % | ||
| 5 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 6 | TMO | 6.2 | 5.5 | 266Md USD | 37.9x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 24.6 % | ||
| 7 | LONN | 5.6 | 4.7 | 54.1Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.5 % | 22.7 % | ||
| 8 | MTD | 5.3 | 4.9 | 34.8Md USD | 37.9x | 22.2 % | 6.3 % | 47.4 % | 1.8x | 2.5 % | 21.0 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
